Mark S Roberts
Overview
Explore the profile of Mark S Roberts including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
158
Citations
3142
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Williams K, Krauland M, Nowalk M, Nowalk M, Harrison L, Williams J, et al.
J Infect
. 2025 Feb;
90(3):106443.
PMID: 39952478
Objectives: Availability of caregiver-administered nasal spray live attenuated influenza vaccine (LAIV) raises the potential for increased influenza vaccine uptake. Direct and indirect benefits (decreased influenza cases and hospitalizations) of increased...
2.
Bilden R, Roberts M, Stein B, Jones D
Subst Use Addctn J
. 2024 Dec;
:29767342241303583.
PMID: 39676259
Background: Opioid overdose rates continue to rise in the United States while access to treatment options remains limited. The X waiver, which allowed clinicians to prescribe buprenorphine, a medication for...
3.
Tiwari K, Rahimian M, Roberts M, Kumar P, Buchanich J
Sci Rep
. 2024 Nov;
14(1):29563.
PMID: 39609532
The US opioid overdose epidemic has been a major public health concern in recent decades. There has been increasing recognition that its etiology is rooted in part in the social...
4.
Williams K, Krauland M, Harrison L, Williams J, Roberts M, Zimmerman R
Am J Public Health
. 2024 Nov;
115(2):209-216.
PMID: 39541556
To estimate the effect of influenza vaccination disparities. We compared symptomatic influenza cases between Black and White races in 2 scenarios: (1) race- and age-specific vaccination coverage and (2) equal...
5.
Krauland M, Roberts M
MDM Policy Pract
. 2024 Jun;
9(1):23814683241260744.
PMID: 38911124
Highlights: Nonpharmaceutical interventions were used extensively during the early period of the COVID-19 pandemic, but their use has remained controversial.Agent-based modeling of the impact of these mitigation strategies early in...
6.
Lonn S, Krauland M, Fagan A, Sundquist K, Roberts M, Kendler K
J Stud Alcohol Drugs
. 2023 Aug;
84(6):863-873.
PMID: 37650838
Objective: Drug use disorder (DUD) is a worldwide problem, and strategies to reduce its incidence are central to decreasing its burden. This investigation seeks to provide a proof of concept...
7.
Krauland M, Zimmerman R, Williams K, Raviotta J, Harrison L, Williams J, et al.
Vaccine X
. 2022 Dec;
13:100249.
PMID: 36536801
Introduction: Current influenza vaccines have limited effectiveness. COVID-19 vaccines using mRNA technology have demonstrated very high efficacy, suggesting that mRNA vaccines could be more effective for influenza. Several such influenza...
8.
Williams K, Krauland M, Harrison L, Williams J, Roberts M, Zimmerman R
Vaccines (Basel)
. 2022 Nov;
10(11).
PMID: 36366307
Older adults (age ≥ 65) are at high risk of influenza morbidity and mortality. This study evaluated the impact of a hypothetical two-dose influenza vaccine regimen per season to reduce...
9.
Richards-Shubik S, Roberts M, Donohue J
J Health Econ
. 2022 May;
83:102616.
PMID: 35504211
Unlike demand studies in other industries, models of provider demand in health care often must omit a price, or any other factor that equilibrates the market such as a waiting...
10.
Krauland M, Galloway D, Raviotta J, Zimmerman R, Roberts M
Am J Prev Med
. 2022 Mar;
62(4):503-510.
PMID: 35305778
Introduction: Interventions to curb the spread of COVID-19 during the 2020-2021 influenza season essentially eliminated influenza during that season. Given waning antibody titers over time, future residual population immunity against...